Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs... see more

TSX:TH - Post Discussion

Theratechnologies Inc > Sun­len­ca
View:
Comment by palinc2000 on Dec 24, 2022 8:34am
https://seekingalpha.com/pr/19064823-sunlenca-lenacapavir-receives-fda-approval-first-in-class-twice-yearly-treatment-option-for
Comment by scarlet1967 on Dec 24, 2022 10:08am
sunlenca-epar-product-information_en sunlenca-epar-product-information_en Sunlenca (lenacapavir) dosing, indications, interactions, adverse effects, and more Trogarzo (ibalizumab) dosing, indications, interactions, adverse effects, and more Its new drug with new MOA post approval studies need to verify some of potential risks for instance using it for patients with kidney and liver ...more  
Comment by scarlet1967 on Dec 24, 2022 8:47pm
“CAPELLA was conducted in 72 heavily treatment-experienced patients with multiclass resistant HIV-1. Patients were required to have a viral load ≥ 400 copies/mL, documented resistance to at least two antiretroviral medicinal products from each of at least 3 of the 4 classes of antiretroviral medicinal products (NRTI, NNRTI, PI and INSTI), and no more than 2 fully active antiretroviral medicinal ...more  
Comment by Trogarzon on Dec 26, 2022 10:08am
I don't remember who said you own it talking about family members invested in Thera.  But it's pretty nasty this year, lot of people who would of, could of, should of.  Yep, I hope and pray for a vengeance day soon enought.  Been there before but this years pause is nasty for the ego.  Lot of people in line to humiate you publicly, even the wife.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities